Risk Factors Update Summary

• Increased scrutiny on ESG matters may lead to additional costs and risks, impacting investor perception.
• Sales of respiratory products decreased from 44% to 24% of total revenues.
• Potential costs and liabilities due to data privacy and security breaches could result in significant harm.
• Loss of EUA approvals by the FDA for respiratory products could adversely impact operations.
• Changes in tax laws, especially retroactively, could adversely affect financial statements and operations.
• Unexpected increases in demand could require significant additional costs to meet customer demand.
• Failure to comply with evolving privacy laws may result in penalties, impacting business reputation.
• Failure to integrate Quidel and Ortho businesses could harm results and prospects.
• Pension plan liabilities of approximately $36.0 million could affect financial condition as they mature.
• Increased cybersecurity risks due to flexible work arrangements may create vulnerabilities.
• Failure to attract or retain key employees may impede R&D and operational objectives.
• Disruptions in supply chain, logistics, and labor availability could impact production and operations.
• Future sales of common stock by significant investors could impact the trading price.
• Changes in import tariffs or restrictions could negatively impact business by affecting demand and costs.